Bio Blast Pharma Receives Orphan Drug Designation From U.S. FDA for Cabaletta For The Treatment Of Spinocerebellar Ataxia Type 3

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.